← Eichor
Study identifier: NCT04589754 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Adriamycin and Ifosfamide Combined With Sintilimab

Condition: Soft Tissue Sarcoma  ·  Sponsor: Sun Yat-sen University

PhasePhase 2
Planned participants176
Who can joinAll sexes, 14 Years to 70 Years
Healthy volunteersNo

About this study

The aim of this study was to explore the efficacy and safety of adriamycin and ifosfamide combined with sintilimab versus chemotherapy in the treatment of advanced or unresectable soft tissue sarcoma.

This description comes directly from the study's public registry record.

Talk to the study team

Xing Zhang  ·  020-87343383  ·  zhangxing@sysucc.org.cn

Always discuss trial participation with your own doctor first.

Locations (1)

Xing ZhangGuangzhou, Guangdong, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04589754